AIM
CLDX icon

AXA Investment Managers’s Celldex Therapeutics CLDX Stock Holding History

AXA Investment Managers’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$3.14M Buy
+121,326
New +$2.81M 0.01% 675

Other funds holding CLDX

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AXA Investment Managers's CLDX Position: Q3 2025 in Review

AXA Investment Managers opened a new position in Celldex Therapeutics (CLDX) in Q3 2025: 121,326 shares worth $3.14M. The stake represents 0.01% of the portfolio and ranks #675 among its holdings.

184 funds tracked by Wall St. Rank hold CLDX as of Q3 2025.

  • AXA Investment Managers held 121,326 shares of Celldex Therapeutics worth $3.14M as of Q3 2025.
  • Celldex Therapeutics was a new AXA Investment Managers position in Q3 2025.
  • Celldex Therapeutics made up 0.01% of AXA Investment Managers's portfolio in Q3 2025, its #675 holding.
  • 184 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2025.

Based on AXA Investment Managers's 13F filing for Q3 2025, filed 14 Nov 2025.